A Johns Hopkins University-led team has created an inexpensive portable device and cellphone app to diagnose gonorrhea in less than 15 minutes and determine if a particular strain will respond to frontline antibiotics.
The invention improves on traditional testing in hospital laboratories and clinics, which typically takes up to a week to deliver results—time during which patients can unknowingly spread their infections. The team’s results appear today in Science Translational Medicine.
GERMANTOWN, Md. & HILDEN, Germany–(BUSINESS WIRE)–QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the fast and easy-to-use QIAreach® Anti-SARS-CoV-2 Total Test.
In a news cycle dominated by vaccines and an economy focused on innovation, cities see life sciences as not just a good bet but a critical piece of their economic development future. But while many metros believe they can attract jobs with increased investment in lab space, only a relative handful can become new centers of industry growth.
Image: Courtesy Hines Levit Green, a forthcoming development in Houston, exemplifies the spread of life sciences campuses across the U.S.
Breakthrough discoveries and unprecedented capital funding have heightened the dynamic nature of the life sciences industry. This surge of resources should fuel a new level of growth in research & development (R&D) and accelerate the demand for quality manufacturing space.
A longtime pediatric anesthesiologist at Children’s National Hospital, Dr. Julia Finkel has long wanted a more objective way to measure how much pain patients are feeling.
“For pain, we do it very empirically,” Dr. Finkel said. “The patient says they hurt, we give them a drug. They either feel better or they don’t…It’s done in a very empirical way without a physiologic measure, and there are consequences for that.”
Image: https://technical.ly/
About the business: TaylorMade Experience is a Silver Spring-based event management business that also assists clients with fundraising efforts. It is a certified woman-owned small business, has about a dozen employees, and ranked 15th among the Washington Business Journal’s most recent List of largest meeting and event planning companies based on the 40 local events it held in 2019.
Image: Christina Taylor launched TaylorMade Experience in 2008 as an events management business but made the pivot to all-virtual events during the pandemic. TAYOR-MADE EVENTS
Johns Hopkins University and Bloomberg Philanthropies today announced the launch of a $150 million effort to directly address historic underrepresentation in science, technology, engineering, and math fields, and to prepare a new, more diverse generation of researchers and scholars to assume leading roles in tackling some of the world’s greatest challenges.
ROCKVILLE, Md., May 12, 2021 /PRNewswire/ — Emmes (the “Company”), a global, full-service Clinical Research Organization (CRO) dedicated to supporting the advancement of public health and biopharmaceutical innovation and a portfolio company of Behrman Capital, today announced that it has acquired Orphan Reach, a CRO specialized in clinical research related to rare diseases. Financial terms of the transaction were not disclosed.
Set on the historic Walter Reed Army Medical Center, the Children’s National Research & Innovation Campus will be a one-of-kind innovation hub. The nearly 12-acre campus will house leading entrepreneurs, thinkers, innovators and experts aiming to improve the health and well-being of patients around the world. Johnson & Johnson Innovation – JLABS @ Washington, DC will occupy a 32,000—square foot facility open to biotech, medical device, consumer and health technology start-ups aiming to develop new medicines, medical devices, precision diagnostics and health tech applications. Additionally, in collaboration with the Biomedical Advanced Research and Development Authority (BARDA), a component of the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services, JLABS @ Washington, DC will be the hub for BLUE KNIGHT. Blue Knight is a collaboration dedicated to and aimed at anticipating health security threats, activating the global innovation community, and amplifying technological advancements to prepare for and respond to our rapidly evolving global health environment. We look forward to the opening of JLABS @ Washington, DC in collaboration with our partners at Children’s National Hospital and BARDA to support innovation for patients.
GAITHERSBURG, Md.–(BUSINESS WIRE)–Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that the company has closed a $40.75 million Series B investment round led by Deerfield Management Company. Also joining the Series B round are existing investor Mayo Clinic and an additional undisclosed institutional investor. Proceeds of this financing will be used to accelerate clinical development of PhageBank™ phage therapies, as well as for general corporate purposes.
